Serum concentrations of NSE and S100B in spinocerebellar ataxia type 3/Machado-Joseph disease

Journal of Central South University (Medical Sciences)

Volumn 36, Issue 6, 2011, Pages 504-510

  Zhou, Jie ^a   Lei, Lifang ^a   Shi, Yuting ^a   Wang, Junling ^a   Jiang, Hong ^a,b   Shen, Lu ^a,b   Tang, Beisha ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Biochemical markers; Machado Joseph disease; Neuron specific enolase (nse); Protein s 100 b(s100b); Spinocerebellar ataxia type 3

Indexed keywords

BIOLOGICAL MARKER; ENOLASE; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; HUMAN; MACHADO JOSEPH DISEASE; MALE; MIDDLE AGED;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MACHADO-JOSEPH DISEASE; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PHOSPHOPYRUVATE HYDRATASE; S100 PROTEINS;

EID: 79960828453     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1672-7347.2011.06.006     Document Type: Article

References (34)

1. Schöls L, Bauer P, Schmidt T, et al. Autosomal dominant cer-ebellar ataxias: clinical features, genetics, and pathogenesis [J]. Lancet Neurol, 2004, 3(5): 291-304. (Pubitemid 38510200)
2. Soong B W, Paulson H L. Spinocerebellar ataxias: an update [J]. Curr Opin Neurol, 2007, 20(4): 438-446. (Pubitemid 47051992)
3. Duenas A M, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias [J]. Brain, 2006, 129 (P16) : 1357-1370. (Pubitemid 43999370)
4. Manto M U. The wide spectrum of spinocerebellar ataxia (SCAs) [J]. Cerebellum, 2005, 4(1): 2-6.
5. Schols L, Vieira-Saecker A M, Schols S, et al. Trinucleotide expansion within the MJD1 gene presents clinically as spinocerebellar ataxia and occurs most frequently in German SCA patients[J]. Hum Mol Genet, 1995, 4(6): 1001-1005.
6. Takiyama Y, Nishizawa M, Tanaka H, et al. The gene for Machado-Joseph disease maps to human chromosome 14q[J]. Nat Genet, 1993, 4(3): 300-304. (Pubitemid 23205181)
7. Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1[J]. Nat Genet, 1994, 8(3): 221-228. (Pubitemid 24338732)
8. WANG Junling, XU Qian, LEI Lifang, et al. Frequency of spinocerebellar ataxia types 1,2,3,6,7,8,10,12,17 and dentatorubral-pallidoluysian atrophy in Chinese Han population [J]. Chin J Neurol, 2009, 42(10): 672-675.
9. Riess O, Rub U, Pastore A, et al. SCA3: Neurological features, pathogenesis and animal models[ J]. Cerebellum, 2008, 7(2), 125-137.
10. Schmidt T, Lindenberg K S, Krebs A, et al. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions [J]. Ann Ncurol, 2002, 51(3): 302-310. (Pubitemid 34206286)
11. Maruyama H, Nakamura S, Matsuyama Z, et al. Molecular features of the CAG repeats and clinical manifestation of Machado-Joseph disease [J]. Hum Molecul Genet, 1995, 4 (5): 807-812.
12. van de Warrenburg B P, Sinke R J, Verschuuren-Bemelmans C C, et al. Spinocerebellar ataxias in the Netherlands:Prevalence and age at onset variance analysis[ J ]. Neurology, 2002, 58(5): 702-708. (Pubitemid 34211547)
13. Maciel P, Gaspar C, DeStefano A L, et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease[J]. Am J Hum Genet, 1995, 57(1): 54-61.
14. Rub U, Brunt E R, Deller T. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease) [J]. Curr Opin Neurol, 2008, 21 (2): 111-116. (Pubitemid 351644149)
15. Kaiser E, Kuzmits R, Pregant P, et al. Clinical biochemistry of neuron specific enolase[J]. Clinica Chimica Acta, 1989, 183(1): 13-32. (Pubitemid 19179559)
16. Rothermundi M, Peters M, Prehn J H, et al. S100B in Brain Damage and Neurodegeneration[ J]. Micros Res Tech, 2003, 60(6): 614-632.
17. Yardan T, Erenler A K, Baydin A, et al. Usefulness of S100B Protein in Neurological Disorders [J]. J Pak Med Assoc, 2011, 61(3): 276-281.
18. Steiner J, Bogerts B, Schroeter M L, et al. S100B protein in neurodegenerative disorders[ J]. Clin Chem lab Med, 2011, 49 (3): 409424.
19. Schmitz-Hubsch T, Tezenas du Monteel S, Baliko L, et al. Reliability and validity of the international cooperative ataxia rating scale: A study in 156 spinocerebellar ataxia patients [J]. Mov Disord, 2006, 21(5): 699-704. (Pubitemid 43792755)
20. Schmitz-Hubsch T, Tezenas du Monteel S, Baliko L, et al. Scale for the assessment and rating of ataxia development of a new clinical scale[J]. Neurology, 2006, 66(11): 1717-1720. (Pubitemid 43964628)
21. ] Kövesdi E, Lückl J, Bukovics P, et al. Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics[J]. Acta Neurochir, 2010, 152(1): 1-17.
22. Kaca-Orynska M, Tomasiuk R, Friedman A. Neuron-specific enolase and S 100B protein as predictors of outcome in ischaemic stroke[J]. Neurol Neurochir Pol, 2010, 44, (5): 459-463.
23. Lee S Y, Choi Y C, Kim J H, et al. Serum neuron-specific enolase level as a biomarker in differential diagnosis of seizure and syncope[J]. J Neurol, 2010, 257(10): 1708-1712.
24. Palumbo B, Siepi D, Sabalich I, et al. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? [J]. Funct Neurol, 2008, 23(2): 93-96.
25. Kohira I, Tsuji T, Ishizu H, et al. Elevation of neuron-specific enolase in serum and cerebrospinal fluid of early stage Creutzfeldt-Jakob disease[J]. Acta Neurol Scand, 2000, 102(6): 385-387.
26. Tort A B, Portela I. V, Rockenbach I C, et al. S100B and NSE serum concentrations in Machado Joseph disease [J]. Clinica Chimica Acta, 2005, 351 (1/2) :143-148. (Pubitemid 39563568)
27. Teepker M, Munk K, Mylius V, et al. Serum Concentrations of s100b and NSE in Migraine[J]. Headach, 2009, 49(2): 245-252.
28. Schenatto C B, Xavier R M, Bredemeier M, et al. Raised serum S100B protein levels in neuropsychiatrie lupus[J]. Ann Rheum Dis, 2006, 65(6): 829-831. (Pubitemid 43799188)
29. Jesse S, Steinacker P, Cepek L, et al. Glial fibrillary acidic protein and protein S100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease[J]. J Alzheimers Dis, 2009, 17(3) : 541-551.
30. Petzold A, Jenkins R, Watt HC, et al. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease [J]. Neurosci Lett, 2003, 336(3): 167-170. (Pubitemid 36050109)
31. Schaf D V, Tort A B, Fricke D, et al. S100B and NSE serum levels in patients with Parkinson's disease [J]. Parkinsonism Relat Disord, 2005, 11(1): 3943.
32. Otto M, Bahn E, Wiltfang J, et al. Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis[ J]. Neurosci Lett, 1998, 240(3): 171-173. (Pubitemid 28079049)
33. M L Chaves, Camozzato A L, Ferreira E D, et al. Serum levels of S100B and NSE proteins in Alzheimer's disease patients [J]. J Neuroinflammation, 2010, 7: 6.
34. Vig P J, Hearst S, Shao Q, et al. Glial S100B protein modulates mutant ataxin-1 aggregation and toxicity: TRTK12 Peptide, a potential candidate for SCA1 therapy[J]. Cerebellum, 2011, 10(2): 254-266.